Table 1 Rheumatoid arthritis characteristics of the 30-day mortality group at ICU admission

Age (years)

68.3 ± 13.5

(70, 33–96)

66.9 ± 14.4

(70, 33–96)

73.1 ± 8.5

(75, 54–85)

Sex (female/male)

47/20

(70%/30%)

39/13

(75%/25%)

8/7

(53%/47%)

RA duration (years)

13.9 ± 15.0

(10, 0–61)

14.1 ± 15.7

(9, 0–61)

12.9 ± 12.9

(10, 1–48)

 Stage (I/II/III/IV)

9/19/18/21

(13%/28%/27%/31%)

9/15/14/17

(13%/29%/27%/31%)

2/4/4/5

(13%/27%/27%/33%)

 Class (1/2/3/4)

7/16/38/6

(10%/24%/57%/9%)

8/14/29/4

(12%/25%/56%/8%)

1/3/9/2

(7%/20%/60%/13%)

 bDMARDs

6 (9%)

6 (12%)

0 (0%)

 csDMARDs

37 (55%)

30 (57.7%)

7 (46.7%)

 MTX

19 (28%)

17 (33%)

2 (13%)

 MTX dose (mg)

6.4 ± 2.1 (6, 4–12)

6.2 ± 1.7 (6, 4–8)

8.0 ± 5.7 (8, 4–12)

 Others^a

24 (36%)

18 (35%)

6 (40%)

 Glucocorticoids

53 (79%)

38 (73.1%)

15 (100%)

 Glucocorticoid dose (mg)

(conversion of prednisone)

5.3 ± 5.3

(5, 0–25)

4.5 ± 5.0

(4, 0–25)

8.1 ± 5.8

(7, 1–25)

30-day mortality

15/67 (22%)

90-day mortality

18/67 (27%)

1-year mortality

23/62 (37%)